Vernalis plc (LON:VER) released its earnings results on Tuesday. The company reported GBX (4.10) (($0.05)) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of GBX (4.50) (($0.06)) by GBX 0.40 ($0.01), Digital Look Earnings reports. The firm had revenue of GBX 207.90 billion during the quarter. Vernalis plc had a negative return on equity of 22.58% and a negative net margin of 198.87%.

Shares of Vernalis plc (LON:VER) traded up 0.000% during midday trading on Thursday, reaching GBX 15.625. 27,100 shares of the company’s stock were exchanged. The stock’s market capitalization is GBX 82.24 million. Vernalis plc has a 12-month low of GBX 15.00 and a 12-month high of GBX 45.13. The firm has a 50-day moving average of GBX 16.74 and a 200-day moving average of GBX 19.62.

VER has been the subject of a number of recent research reports. N+1 Singer reiterated a “hold” rating and issued a GBX 28 ($0.36) target price on shares of Vernalis plc in a research note on Monday, August 7th. RX Securities restated a “buy” rating on shares of Vernalis plc in a research report on Monday, August 7th. Stifel Nicolaus cut their price objective on shares of Vernalis plc from GBX 24 ($0.31) to GBX 21 ($0.27) and set a “hold” rating for the company in a research report on Monday, August 7th. Finally, Panmure Gordon reaffirmed a “hold” rating and set a GBX 31 ($0.40) target price on shares of Vernalis plc in a report on Monday, August 7th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of GBX 39.40 ($0.51).

TRADEMARK VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.